Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Mar 5, 2024

31100_dirs_2024-03-04_5083dbc5-5729-4f4e-8f35-29edf1f71a73.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-02-29

Reporting Person: Cowan Elvia (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-29 Common Stock A 5400 Acquired 13158 Direct
2024-03-01 Common Stock M 11000 $25.92 Acquired 24158 Direct
2024-03-01 Common Stock S 2322 $73.084 Disposed 21836 Direct
2024-03-01 Common Stock S 4455 $73.689 Disposed 17381 Direct
2024-03-01 Common Stock S 4901 $74.9 Disposed 12480 Direct
2024-03-02 Common Stock F 324 $71.55 Disposed 12156 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-29 Stock Option (right to buy) $73.82 A 25000 Acquired 2024-02-28 Common Stock (25000) Direct
2024-03-01 Stock Option (right to buy) $25.92 M 11000 Disposed 2032-08-08 Common Stock (11000) Direct

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F2: Includes 457 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023.

F3: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.365. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.465. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.47 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F7: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F8: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F9: 1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.